MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, PLSE had -$12,416K decrease in cash & cash equivalents over the period. -$14,628K in free cash flow.

Cash Flow Overview

Change in Cash
-$12,416K
Free Cash flow
-$14,628K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Stock-based compensation
    • Accrued liabilities
    • Proceeds from exercises of stock...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Lease liabilities, net
    • Accounts payable
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-18,581 -17,433 -55,348 -
Depreciation
88 93 90 223
Amortization of intangible assets
167 166 166 333
Stock-based compensation
1,912 4,970 5,617 10,870
Non-cash lease expense
308 306 847 -
Write-off of deferred issuance costs
281 ---
Loss on disposal of fixed assets
-0 --
Other
-62 ---
Accounts receivable
-55 259 15 -
Inventory
70 79 57 -
Prepaid expenses and other current assets
129 374 538 -
Other receivables
--14 -
Other non-current assets
-3 -14 28 -
Accounts payable
-148 -186 1,318 -
Accrued liabilities
1,832 -1,627 -1,823 -
Lease liabilities, net
-375 -360 -1,008 -
Net cash used in operating activities
-14,595 -14,755 -13,039 -26,328
Purchases of property and equipment
33 105 62 148
Purchases of intangible assets
-0 0 20
Net cash used in investing activities
-33 -105 -62 -168
Proceeds from issuance of common stock under employee stock purchase plan
465 -7 241 352
Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs
-0 0 -
Proceeds from exercises of warrants, net of issuance costs
130 1 17 14,063
Proceeds from exercises of stock options
1,674 387 1,708 392
Payment of deferred issuance costs in relation to registration statements
57 0 0 0
Net cash provided by financing activities
2,212 381 1,966 14,807
Net (decrease) increase in cash and cash equivalents
-12,416 -14,479 -11,135 -11,689
Cash and cash equivalents at beginning of period
95,214 -118,038 -
Cash and cash equivalents at end of period
68,319 -95,214 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from exercisesof stock options$1,674K Proceeds from issuance ofcommon stock under...$465K Proceeds from exercisesof warrants, net of...$130K Net cash provided byfinancing activities$2,212K Canceled cashflow$57K Net (decrease)increase in cash and cash...-$12,416K Canceled cashflow$2,212K Stock-based compensation$1,912K Accrued liabilities$1,832K Non-cash lease expense$308K Write-off of deferredissuance costs$281K Amortization of intangibleassets$167K Depreciation$88K Other-$62K Accounts receivable-$55K Other non-currentassets-$3K Payment of deferredissuance costs in...$57K Net cash used inoperating activities-$14,595K Canceled cashflow$4,708K Net cash used ininvesting activities-$33K Net loss-$18,581K Lease liabilities,net-$375K Accounts payable-$148K Prepaid expenses andother current assets$129K Inventory$70K Purchases of property andequipment$33K

PULSE BIOSCIENCES, INC. (PLSE)

PULSE BIOSCIENCES, INC. (PLSE)